Younus M, et al. - Researchers evaluated the long-term impact of treatment with latanoprost on ocular development and safety in pediatric patients with glaucoma and ocular hypertension. In these patients, they noted an acceptable safety profile of latanoprost with no evidence of inducing clinically meaningful or statistically significant changes in ocular development or ocular hyperpigmentation. In best corrected visual acuity (BCVA) change from baseline, corneal thickness or ocular hyperpigmentation, the latanoprost and the non-prostaglandin (non-PG) groups demonstrated no statistically significant difference.